Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
10/19 MERCK : Darmstadt, Germany, Brings Customers Closer to Gene Therapy Product Comm..
10/13 MERCK : MilliporeSigma Opens New Life Science Center in Massachusetts for Scient..
10/12 MERCK : The Millipore Curiosity Cube
10/12 MERCK : Learning in the Cube
10/12 MERCK KGAA : gives back to society through Merck Foundation’s program to i..
10/11 MERCK KGAA : Release according to Article 26, Section 1 of the WpHG [the German ..
10/11 MERCK : Hosts Leading Scientists at Life Science Symposium in Greater Boston
10/11 MERCK : Darmstadt, Germany, Opens New Life Science Center for Scientific Collabo..
10/11 MERCK : Presents 'Future Forum' at Boston's HUBweek 2017
10/09 MERCK KGAA : gives back to society through Merck Foundation's program to improve..
More news
News from SeekingAlpha
10/13 Merck KGaA's Bavencio an Orphan Drug for gastric cancer
09/28 Merck KGaA (MKGAY) Investor Presentation - Slideshow
09/28 YOUR DAILY PHARMA SCOOP : Celgene's CELMoD Potential, Allergan's Senate Troubles..
09/27 Pfizer and Merck KGaA's Bavencio OK'd in Japan for rare skin cancer
09/24 WEEK IN REVIEW : Zai Lab Completes $150 Million U.S. IPO; Investors Push Valuati..
Financials (€)
Sales 2017 15 390 M
EBIT 2017 3 450 M
Net income 2017 1 737 M
Debt 2017 9 928 M
Yield 2017 1,34%
P/E ratio 2017 21,99
P/E ratio 2018 20,17
EV / Sales 2017 1,44x
EV / Sales 2018 1,29x
Capitalization 12 215 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 110 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-4.68%14 409
ABBVIE53.37%153 097
KYOWA HAKKO KIRIN CO LTD24.78%10 167
JAZZ PHARMACEUTICALS PLC28.83%8 437
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 792
CONVATEC GROUP-9.02%5 572